CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Related Clinical Trial
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5) CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia AML Therapy With Irradiated Allogeneic Cells Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Brief Title

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Official Title

Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Brief Summary

      The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older
      participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to
      receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after
      Hypomethylating Agents (HMA) failure.
    

Detailed Description

      Currently, elderly patients with AML and high risk MDS, who are ineligible to receive
      induction chemotherapy and fail HMA +/- combination, have very poor outcomes and there is no
      FDA-approved therapy outside of some targeted therapies which can only be applied to a small
      patient population. CPX-351 is an investigational (experimental) drug that works by combining
      two anti-cancer drugs cytarabine and daunorubicin. CPX-351 is experimental because it is only
      FDA approved for the treatment of adults with two types of AML: newly diagnosed
      therapy-related AML or AML with myelodysplasia-related changes.

      This is an open label clinical trial of lower doses of CPX-351 in relapsed/primary refractory
      older AML and MDS patients ineligible to receive intensive chemotherapy. The first arm is for
      particpants with primary refractory/relapsed AML and the second arm is for higher risk MDS
      participants after HMA failure.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Overall response rate (ORR) per 2003 International Working Group (IWG) criteria

Secondary Outcome

 Time to response (TTR)

Condition

Refractory Acute Myeloid Leukemia

Intervention

CPX-351

Study Arms / Comparison Groups

 Primary refractory/relapsed AML
Description:  Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

20

Start Date

January 14, 2021

Completion Date

December 2025

Primary Completion Date

December 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Primary refractory or relapsed AML (defined by 2016 World Health Organization [WHO]
             criteria) patients who are not suitable for or not willing to receive intensive
             chemotherapy as evaluated by the treating physician. Primary refractory disease is
             defined as:

               -  Failure to achieve a CR, CRi, or mLFS (defined as <5% Bone Marrow (BM) blasts)
                  after receiving 1 or 2 cycles of remission induction chemotherapy.

               -  Failure to achieve a CR, CRi, or MLFS (defined as <5% BM blasts) after receiving
                  4 cycles of non-intensive chemotherapy or whose disease progressed at any time
                  point during the treatment.

          -  Participants with MDS (according to 2016 WHO criteria) who did not respond to
             treatment with azacitidine, decitabine, or combination of HMA with another drug or
             lost their response to initial therapy with HMA.

          -  Eastern Cooperative Oncology Group (ECOG) performance status <=2

          -  Adequate hepatic (serum total bilirubin < 1.5 x ULN, Serum glutamic pyruvic
             transaminase (SGPT) and/or serum glutamate oxaloacetate transaminase (SGOT) <2.5 x
             ULN) and renal function (creatinine < 1.5mg/dL).

          -  Participants must be willing and able to review, understand, and provide written
             consent before starting therapy.

        Exclusion Criteria:

          -  Active signs or symptoms of central nervous system (CNS) involvement by malignancy
             (lumbar puncture [LP] not required).

          -  Prior 7+3 remission induction chemotherapy for MDS or AML

          -  More than 2 lines of prior non-intensive therapy.

          -  New York Heart Association (NYHA) class III or IV heart disease, active ischemia or
             any other uncontrolled cardiac condition such as angina pectoris, clinically
             significant cardiac arrhythmia on rhythm control strategy or on pacemaker,
             uncontrolled hypertension (blood pressure > 160 systolic and > 110 diastolic not
             responsive to antihypertensive medication)

          -  Acute myocardial infarction in the previous 12 weeks (from the start of treatment).

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that, in
             the view of the treating physician, would place the participant at an unacceptable
             risk if he or she were to participate in the study or would prevent that person from
             giving informed consent.

          -  Any active malignancy (unrelated, non-hematological malignancy) diagnosed within the
             past 6 months of starting the study drug (other than curatively treated
             carcinoma-in-situ of the cervix or non-melanoma skin cancer).

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to CPX-351.

          -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Known history of HIV or active hepatitis B or C.

          -  No major surgery within 2 weeks prior to study enrollment.

          -  Pregnant or breast feeding

          -  Male and female participants who are fertile who do not agree to use an effective
             barrier methods of birth control (i.e. abstinence) to avoid pregnancy while receiving
             study treatment and for 30 days after last dose of study treatment. Non-childbearing
             is defined as > 1 year postmenopausal or surgically sterilized.

          -  Acute promyelocytic leukemia (APL)
      

Gender

All

Ages

60 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Sudipto Mukherjee, MD, PhD, 1-866-223-8100, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT04668885

Organization ID

CASE1920


Responsible Party

Sponsor

Study Sponsor

Case Comprehensive Cancer Center


Study Sponsor

Sudipto Mukherjee, MD, PhD, Principal Investigator, Cleveland Clinic, Case Comprehensive Cancer Center


Verification Date

January 2021